Med-Tech Business Strategic Opportunity to Enter the Hearing Screening Market: IP Assets for Sale

Metis Partners presents an exciting opportunity to acquire the intellectual property (“IP”) portfolio of Hearing Diagnostics Limited (“Hearing Diagnostics” or the “Company”), a UK-based med-tech company transforming the way hearing loss is detected. We are actively seeking offers for the Company’s proprietary spatial audio screening system and supporting IP assets, which underpin its innovative approach to hearing care.

Backed by circa £2.5 million in private equity and grant funding, Hearing Diagnostics has developed Audimetroid, a wireless, user-friendly hearing screening solution designed for non-clinical environments. The system combines real-time motion tracking, binaural audio synthesis, and predictive test logic to deliver fast, automated assessments via a smartphone interface—without the need for clinical infrastructure or customer support.

The technology has been commercialised under the HearLead brand, a consumer-facing engagement tool tailored for adults aged 50+, and actively marketed to retail chains and hearing aid manufacturers. The Company is now seeking a buyer to support a strategic shift in commercial direction and unlock new opportunities for adoption.

• Clinically Validated Technology: Audimetroid delivers 99% sensitivity in identifying hearing loss, using spatial audio and behavioural response analysis to enable accurate, automated assessments.
• Strong IP Foundation: Includes a granted European patent and US application covering core innovations such as spatial audio simulation, motion tracking, and real-time audio processing.
• Ready-to-Transfer IP Portfolio: Well-documented and organised for seamless handover, enabling immediate entry into a market projected to reach over 700 million people with disabling hearing loss by 2050[1] (WHO).
• Additional IP Assets: Includes proprietary software, hardware design files, CE marking documentation, technical notes, and five domain names supporting both clinical and consumer-facing offerings.